Literature DB >> 18805555

Are neonatal stem cells as effective as adult stem cells in providing ischemic protection?

Troy A Markel1, Paul R Crisostomo, Maiuxi C Manukyan, Dalia Al-Azzawi, Christine M Herring, Tim Lahm, Nathan M Novotny, Daniel R Meldrum.   

Abstract

BACKGROUND: Bone marrow stem cells (BMSCs) may be a novel treatment modality for organ ischemia, possibly through beneficial paracrine mechanisms. However, stem cells from older hosts exhibit decreased function during stress. We therefore hypothesized that (1) BMSCs derived from neonatal hosts would provide protection to ischemic myocardium, and (2) neonatal stem cells would enhance postischemic myocardial recovery above that seen with adult stem cell therapy.
MATERIALS AND METHODS: Female adult Sprague Dawley rat hearts were subjected to an ischemia/reperfusion protocol via Langendorff isolated heart preparation (15 min equilibration, 25 min ischemia, and 60 min reperfusion). BMSCs were harvested from adult and neonatal mice and cultured through several passages under normal conditions (37 degrees C, 5% CO(2)/air). Immediately prior to ischemia, 1 million adult or neonatal BMSCs were infused into the coronary circulation. Cardiac functional parameters were continuously recorded.
RESULTS: Pretreatment with adult BMSCs significantly increased postischemic myocardial recovery as noted by improved left ventricular developed pressure, end diastolic pressure, contractility, and rate of relaxation. Neonatal stem cells, however, did not cause any noticeable improvement in myocardial functional parameters following ischemia.
CONCLUSION: Neonatal and adult BMSCs are distinctly different in the degree of beneficial tissue protection that they can provide. The data herein suggests that a critical age exists as to when stem cells become fully activated to provide their beneficial protective properties. Defining the genes that initiate these protective properties may allow for genetic amplification of beneficial signals, and the generation of "super stem cells" that provide maximum protection to ischemic tissues.

Entities:  

Mesh:

Year:  2008        PMID: 18805555      PMCID: PMC2929583          DOI: 10.1016/j.jss.2008.03.054

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  36 in total

Review 1.  Stem cells and myocardial repair.

Authors:  Christopher D Raeburn; Michael A Zimmerman; Jyoti Arya; Anirban Banerjee; Alden H Harken
Journal:  J Am Coll Surg       Date:  2002-11       Impact factor: 6.113

2.  The injured child is resistant to multiple organ failure: a different inflammatory response?

Authors:  Casey M Calkins; Denis D Bensard; Ernest E Moore; Robert C McIntyre; Christopher C Silliman; Walter Biffl; Alden H Harken; David A Partrick; Patrick J Offner
Journal:  J Trauma       Date:  2002-12

3.  Estradiol administration improves splanchnic perfusion following trauma-hemorrhage and sepsis.

Authors:  Joachim F Kuebler; Doraid Jarrar; Balazs Toth; Kirby I Bland; Loring Rue; Ping Wang; Irshad H Chaudry
Journal:  Arch Surg       Date:  2002-01

4.  Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential.

Authors:  Alexandra Peister; Jason A Mellad; Benjamin L Larson; Brett M Hall; Laura F Gibson; Darwin J Prockop
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

5.  Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor.

Authors:  Ken-ichi Hiasa; Kensuke Egashira; Shiro Kitamoto; Minako Ishibashi; Shujiro Inoue; Weihua Ni; Qingwei Zhao; Shin Nagata; Makoto Katoh; Masataka Sata; Akira Takeshita
Journal:  Basic Res Cardiol       Date:  2004-01-19       Impact factor: 17.165

6.  Neonatal stem cells exhibit specific characteristics in function, proliferation, and cellular signaling that distinguish them from their adult counterparts.

Authors:  Troy A Markel; Meijing Wang; Paul R Crisostomo; Maiuxi C Manukyan; Jeffrey A Poynter; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-02       Impact factor: 3.619

7.  A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts.

Authors:  Thomas R Payne; Hideki Oshima; Masaho Okada; Nobuo Momoi; Kimimasa Tobita; Bradley B Keller; Hairong Peng; Johnny Huard
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

8.  Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury.

Authors:  Michael J Guzman; Paul R Crisostomo; Meijing Wang; Troy A Markel; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2008-01-16       Impact factor: 2.192

9.  Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function.

Authors:  H Zhang; S-J Zhu; W Wang; Y-J Wei; S-S Hu
Journal:  Gene Ther       Date:  2007-10-18       Impact factor: 5.250

10.  Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease.

Authors:  Zongjin Li; Jenny C Wu; Ahmad Y Sheikh; Daniel Kraft; Feng Cao; Xiaoyan Xie; Manishkumar Patel; Sanjiv S Gambhir; Robert C Robbins; John P Cooke; Joseph C Wu
Journal:  Circulation       Date:  2007-09-11       Impact factor: 29.690

View more
  6 in total

1.  VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function.

Authors:  Troy A Markel; Yue Wang; Jeremy L Herrmann; Paul R Crisostomo; Meijing Wang; Nathan M Novotny; Christine M Herring; Jiangning Tan; Tim Lahm; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-10       Impact factor: 4.733

Review 2.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

3.  Comparison of Preterm and Term Wharton's Jelly-Derived Mesenchymal Stem Cell Properties in Different Oxygen Tensions.

Authors:  Saloni Balgi-Agarwal; Caitlyn Winter; Alexis Corral; Shamimunisa B Mustafa; Peter Hornsby; Alvaro Moreira
Journal:  Cells Tissues Organs       Date:  2018-06-27       Impact factor: 2.481

4.  Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: in vitro and in vivo investigation.

Authors:  Madhur Nayan; Arghya Paul; Guangyong Chen; Ray C J Chiu; Satya Prakash; Dominique Shum-Tim
Journal:  J Tissue Eng       Date:  2011-07-24       Impact factor: 7.813

5.  Efficient labeling in vitro with non-ionic gadolinium magnetic resonance imaging contrast agent and fluorescent transfection agent in bone marrow stromal cells of neonatal rats.

Authors:  Ying-Qin Li; Ying Tang; Rao Fu; Qiu-Hua Meng; Xue Zhou; Ze-Min Ling; Xiao Cheng; Su-Wei Tian; Guo-Jie Wang; Xue-Guo Liu; Li-Hua Zhou
Journal:  Mol Med Rep       Date:  2015-03-23       Impact factor: 2.952

6.  Mechanisms of Age-Dependent Loss of Dietary Restriction Protective Effects in Acute Kidney Injury.

Authors:  Nadezda V Andrianova; Stanislovas S Jankauskas; Ljubava D Zorova; Irina B Pevzner; Vasily A Popkov; Denis N Silachev; Egor Y Plotnikov; Dmitry B Zorov
Journal:  Cells       Date:  2018-10-22       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.